Atlas Trials

Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes

Clinical trial NCT06989723 · RECRUITING

Trial details

NCT number
NCT06989723
Sponsor
Seoul National University Bundang Hospital
Status
RECRUITING
Phase
Phase 4
Study type
INTERVENTIONAL
Type 2 DiabetesFatty Liver
Start date
2025-01-01
Primary completion
2026-12-31
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.